Neuroscience
| 3 min read
The novel stem-cell derived retinal organoid provided a new understanding of the disease by showing that damage to retinal pigment epithelium cells is enough to cause neurodegeneration of photoreceptors.
| 4 min read
Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability.
| 4 min read
Multimodal approaches could help drug developers connect disease biology with clinical outcomes and better understand why treatments succeed or fail. 
| 5 min read
Rodrigo Cristofoletti discusses how cerebral organoids, advanced imaging, and quantitative modeling are helping researchers better understand brain development, disease, and drug discovery.
| 6 min read
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
| 4 min read
As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets.
| 5 min read
New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity.
| 5 min read
By combining genomics, brain imaging, and digital biomarkers, the MAP-D initiative aims to redefine depression through biology rather than symptoms alone.
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 4 min read
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
| 3 min read
Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease.
| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
